By Fineline Cube 
China-based Shanghai Escugen has entered into an exclusive option agreement with US-headquartered ConjugateBio Inc. regarding its EZWi-Fit platform. This next-generation linker payload technology platform offers significant competitive advantages in safety, efficacy, drug resistance, and pharmacokinetic characteristics.
Agreement Details
Under the terms of the agreement, ConjugateBio, upon payment of an option fee to Escugen, secures the exclusive right to utilize Escugen’s EZWi-Fit platform technology for the development of antibody drug conjugate (ADC) products targeting specified therapeutic areas. Upon exercising the option, ConjugateBio will acquire a global exclusive license for these products.
Financial Terms
Escugen stands to receive over USD 100 million in payments tied to development, regulatory, and commercialization milestones. Additionally, the company is entitled to tiered royalties based on the global annual net sales of the licensed products.-Fineline Info & Tech